Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Cellestia Biotech SA is a Swiss biopharmaceutical company focused on pioneering innovative therapeutics for autoimmune diseases and multi-drug resistant cancers. Their lead compound, CB-103, targets the CSL-NOTCH transcription complex, addressing unmet medical needs by developing first-in-class therapies. With a strong emphasis on patient dedication, Cellestia aims to extend and improve the quality of life for patients with limited treatment options. By overcoming dose-limiting toxicities associated with NOTCH inhibitors, Cellestia's approach holds promise in the oncology and autoimmune markets. With an Investigational New Drug (IND) approval in place, CB-103 is set to enter Proof-of-Concept clinical studies for graft-versus-host disease (GvHD), with successful Phase 2 trials demonstrating efficacy in treating patients with multi-drug resistant cancers. Additionally, Cellestia is advancing a range of pre-clinical candidates for chronic autoimmune indications, positioning itself to bring innovative therapies to patients across various medical needs.